Subtype
Uveal Melanoma
CI-CAN-00001637UVMExplore in graph →
59 active trials1 approved drugs17 evidence items
- NCIt
- C7712
- OncoTree
- UM
- DOID
- 6039
- UMLS CUI
- C0220633
- MeSH
- D000098943
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001637UVMExplore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (34)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05607095 | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma | recruiting | Phase 1 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07804186 | Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | recruiting | Phase 3 | 450 | IDEAYA BiosciencesINDUSTRY | 2 | Sep 15, 2026 |
| NCT06070012 | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | recruiting | Phase 2 | 44 | Diwakar DavarOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT06626516 | Tebentafusp-tebn With LDT in Metastatic UM | recruiting | Phase 1 / Phase 2 | 109 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07501117 | Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma | recruiting | Phase 1 | 15 | Inge Marie SvaneOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06246149 | Adjuvant Tebentafusp in High Risk Ocular Melanoma(ATOM) | recruiting | Phase 3 | 290 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jun 30, 2026 | clinicaltrials |
| NCT06932757 | Adjuvant Quisinostat in High-Risk Uveal Melanoma | recruiting | Phase 2 | 63 | University of MiamiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06414590 | Neoadjuvant Tebentafusp for Uveal Melanoma | recruiting | Phase 2 | 19 | Thomas Jefferson UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT07627698 | Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma(DUET-MEL) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis(TRIUMPH) | recruiting | Phase 1 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT07276386 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06550674 | Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma(IGCMU) | recruiting | N/A | 50 | Centre Jean PerrinOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07364474 | Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver | recruiting | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06627244 | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | recruiting | Phase 2 | 30 | University of MiamiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07421739 | Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects | recruiting | — | 15 | Aura BiosciencesINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04424719 | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)(SALOME) | recruiting | N/A | 700 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma(AMUM) | recruiting | Phase 3 | 100 | Gustav StalhammarOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06519266 | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases(SCANDIUM-III) | recruiting | Phase 3 | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05733728 | Retrospective Register for Uveal Melanoma | recruiting | — | 1,400 | Medical University of ViennaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT01438658 | Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma(UM) | recruiting | — | 250 | Hadassah Medical OrganizationOTHER | 1 | Sep 28, 2011 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials